Burosumab Is a ' Game Changer, ' Effective in All Subgroups of XLH Burosumab Is a ' Game Changer, ' Effective in All Subgroups of XLH

As in the overall phase 3 trial population, 24 weeks of burosumab treatment improved serum phosphorus and key measures of pain and stiffness in subgroups of adults with this rare form of inherited rickets.Medscape Medical News
Source: Medscape Orthopaedics Headlines - Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news